Maynard Um
-
-
-
-
-
-
-
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
-
-
-
-
-
-
-
Ensysce Biosciences (ENSC) Misses Q4 EPS by 75c
-
-
-
-
-
-
-
Ensysce reaches 50% enrollment in phase 3 trial for opioid PF614
-
-
-
-
-
-
-
Ensysce begins Phase 3 trial enrollment for pain drug PF614
-
-
-
-
-
-
-
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
-
-
-
-
-
-
-
Ensysce receives FDA guidance on opioid with overdose protection
-
-
-
-
-
-
-
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
-
427,714 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

